The Global Resource For Connecting Buyers and Sellers

Orexo Discloses More Information About the Improved Market Access Position for Zubsolv® US in 2018

UPPSALA, Sweden, Dec. 12, 2017 /PRNewswire/ —
Orexo AB today announces specific information about the improved market access position for Zubsolv (buprenorphine and naloxone) sublingual tablet (CIII) in the US effective January 1, 2018, and previously announced in the Interim Report…